Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer

Programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) modulate antitumor immunity and are major targets of checkpoint blockade immunotherapy. However, clinical trials of anti-PD-L1 and anti-PD-1 antibodies in breast cancer demonstrate only modest efficacy. Further...

Full description

Bibliographic Details
Main Authors: Bogang Wu, Xiujie Sun, Harshita B. Gupta, Bin Yuan, Jingwei Li, Fei Ge, Huai-Chin Chiang, Xiaowen Zhang, Chi Zhang, Deyi Zhang, Jing Yang, Yanfen Hu, Tyler J. Curiel, Rong Li
Format: Article
Language:English
Published: Taylor & Francis Group 2018-11-01
Series:OncoImmunology
Subjects:
breast cancer
immunotherapy
combination therapy
adipocyte
pd-l1
ppargamma antagonist
immune checkpoint
pd-1
inflammation and cancer
new targets
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1500107

Internet

http://dx.doi.org/10.1080/2162402X.2018.1500107

Similar Items